Free Trial
→ Elon Warns 'America Will Go Bankrupt'. Trump's Plan Inside. (From American Hartford Gold) (Ad)tc pixel
NASDAQ:CALC

CalciMedica Q4 2025 Earnings Report

CalciMedica logo
$1.60 -0.05 (-3.03%)
Closing price 10/2/2026 03:56 PM Eastern
Extended Trading
$1.71 +0.11 (+6.81%)
As of 10/2/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

CalciMedica EPS Results

Actual EPS
-$3.45
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CalciMedica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CalciMedica Announcement Details

Quarter
Q4 2025
Date
3/3/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

CalciMedica's next earnings date is estimated for Wednesday, November 11, 2026, based on past reporting schedules.

Conference Call Resources

CalciMedica Earnings Headlines

CalciMedica consensus price target raised 400% to $38.25
September 15, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/calcimedica-consensus-price-target-raised-400-to-38-25/ar-AA2chjFl
CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference-1036527962
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
October 4 at 1:00 AM  |  Stansberry Research (Ad)
CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357483/0/en/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference.html
CalciMedica, Inc. (CALC) Stock Major Holders - Yahoo Finance
September 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/CALC/holders/
CalciMedica Announces 1-for-5 Reverse Stock Split
August 27, 2026  |  rttnews.comhttps://www.rttnews.com/3685726/calcimedica-announces-1-for-5-reverse-stock-split.aspx
See More CalciMedica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email.

About CalciMedica

CalciMedica (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research is centered on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.

CalciMedica’s lead investigational product is Auxora, also known as zelnecirnon or CM4620. The selective CRAC channel inhibitor has been evaluated in clinical studies for conditions including acute pancreatitis and associated acute kidney injury, as well as other diseases involving excessive inflammation. Auxora remains an investigational therapy and has not been approved for commercial use.

CalciMedica was founded in 2007 and is based in La Jolla, California. The company became publicly traded on the Nasdaq under the symbol CALC following a business combination with Graybug Vision that was completed in 2023. Its clinical development activities have primarily involved studies in the United States, with potential applications for its platform being evaluated across multiple inflammatory disease areas.

View CalciMedica Profile
Earnings Tools